<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02482753</url>
  </required_header>
  <id_info>
    <org_study_id>CDM301</org_study_id>
    <nct_id>NCT02482753</nct_id>
  </id_info>
  <brief_title>Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer</brief_title>
  <official_title>A Phase III Trial of Chidamide in Combination With Exemestane in Patients With Hormone Receptor-Positive Advanced Breast Cancer (ACE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chipscreen Biosciences, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chipscreen Biosciences, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was to evaluate the efficacy and safety of Chidamide in combination with&#xD;
      exemestane in postmenopausal patients with hormone-receptor positive advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study including two parts: (1) Part A, open-label design, 20 patients will be enrolled&#xD;
      and receive 30 mg Chidamide BIW and 25 mg exemestane QD. The main object of part A is to&#xD;
      evaluate the pharmacokinetic and pharmacodynamic profile of Chidamide when in combination&#xD;
      with exemestane. (2) Part B, randomized and double-blinded design, 328 patients will be&#xD;
      assigned randomly in a 2:1 ratio to experiment group (30 mg Chidamide BIW + 25 mg exemestane&#xD;
      QD) and control group (placebo BIW + 25 mg exemestane QD), to evaluate the efficacy and&#xD;
      safety of Chidamide when in combination with exemestane in patients with locally advanced or&#xD;
      metastatic estrogen receptor-positive breast cancer progressing on endocrine therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival (PFS), double-blinded period</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years</time_frame>
    <description>PFS is measured from the date of randomization until progression or death, whichever is first met</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetic profiles of Chidamide, open-label period</measure>
    <time_frame>0,1,2,4,8,12,24,48,72 hours after the first dose of Chidamide on day 2 at induced stage (4 days in total); 0,1,2,4,8,12,24,48,72 hours post-dose on day 1 of cycle 1 at combination treatment stage</time_frame>
    <description>The pharmacokinetic parameters include Area under the plasma concentration versus time curve (AUC) , Peak Plasma Concentration (Cmax), time to reach Cmax (Tmax), mean concentration at steady state (Css)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetic profiles of exemestane, open-label period</measure>
    <time_frame>0,1,2,4,8,12,24 hours after the first dose of exemestane on day 1 at induced stage (4 days in total); 0,1,2,4,8,12,24,48,72 hours post-dose on day 1 of cycle 1 at combination treatment stage</time_frame>
    <description>The pharmacokinetic parameters include Area under the plasma concentration versus time curve (AUC) , Peak Plasma Concentration (Cmax), time to reach Cmax (Tmax), mean concentration at steady state (Css)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>acetylation level of histone H3, open-label period</measure>
    <time_frame>pre-dose of Chidamide on day 2 at induced stage (4 days in total); pre-dose of Chidamide on day 1 of cycle 2 at combination treatment stage</time_frame>
    <description>The acetylation level of histone H3 is assayed by enzyme-linked immuno sorbent assay (ELISA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival, double-blinded period</measure>
    <time_frame>Time from randomization to death from any cause, assessed up to 6 years</time_frame>
    <description>OS is measured from the date of randomization until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR), double-blinded period</measure>
    <time_frame>From the first date of response until the date of first documented progression, assessed up to 3years</time_frame>
    <description>DOR is measured from the first date when criteria for response is met until the first date when the criteria for progression is met</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate (ORR), open-label period and double-blinded period</measure>
    <time_frame>Response is assessed once every 6 weeks, assessed up to 3 years</time_frame>
    <description>ORR is defined as percentage of participants with Complete Response and Partial Response, assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical benefit rate (CBR), open-label period and double-blinded period</measure>
    <time_frame>Response is assessed once every 6 weeks, assessed up to 3 years</time_frame>
    <description>ORR is defined as percentage of participants with Complete Response, Partial Response or Stable Disease ≥ 24 weeks, assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS, open-label period</measure>
    <time_frame>Time from the start of treatment to the earliest of documented disease progression, or death, assessed up to 3 years</time_frame>
    <description>PFS is measured from the start of treatment until progression or death, whichever is first met</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">365</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Chidamide + exemestane, open-label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 30 mg Chidamide per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chidamide + exemestane, double-blinded</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 30 mg Chidamide twice per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo + exemestane, double-blinded</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo twice per week and 25 mg exemestane PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>30 mg, administered orally twice per week (BIW)</description>
    <arm_group_label>Chidamide + exemestane, double-blinded</arm_group_label>
    <arm_group_label>Chidamide + exemestane, open-label</arm_group_label>
    <other_name>CS055</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>25 mg, PO daily</description>
    <arm_group_label>Chidamide + exemestane, double-blinded</arm_group_label>
    <arm_group_label>Chidamide + exemestane, open-label</arm_group_label>
    <arm_group_label>placebo + exemestane, double-blinded</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered orally twice per week (BIW)</description>
    <arm_group_label>placebo + exemestane, double-blinded</arm_group_label>
    <other_name>Simulation tablet of Chidamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 ~ 75 years old, postmenopausal women;&#xD;
&#xD;
          2. Histological or cytological confirmation of hormone receptor-positive [estrogen&#xD;
             receptor (ER) positive and progesterone receptors (PgR) positive or negative] breast&#xD;
             cancer;&#xD;
&#xD;
          3. Disease progression or recurrence after at least one endocrine therapy (either in&#xD;
             advanced/metastatic setting or adjuvant setting);&#xD;
&#xD;
          4. ≤4 prior therapies (either in advanced/metastatic setting or adjuvant setting),&#xD;
             patients may have received one prior chemotherapy;&#xD;
&#xD;
          5. The disease condition is inoperable, stage III or stage IV, at least one measurable&#xD;
             lesion or simple bone metastases with no measurable lesions;&#xD;
&#xD;
          6. Last prior therapy intervals: (a) if the last treatment was endocrine therapy, the&#xD;
             interval must ≥ 2 weeks; (b) if the last treatment was chemotherapy therapy, the&#xD;
             interval must ≥ 4 weeks;&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group Performance Status: 0~1;&#xD;
&#xD;
          8. Absolute neutrophil count ≥ 1.5×109 / L, platelet count ≥ 100×109 / L, hemoglobin ≥ 90&#xD;
             g/L;&#xD;
&#xD;
          9. Life expectancy ≥ 3 months;&#xD;
&#xD;
         10. Have signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients have known central nervous system (CNS) metastases or a history of CNS&#xD;
             metastases , or with leptomeningeal disease;&#xD;
&#xD;
          2. Patients with human epidermal growth factor receptor-2 (Her-2) positive;&#xD;
&#xD;
          3. Patients previously received treatment with exemestane;&#xD;
&#xD;
          4. Patients received radiotherapy ≤ 4 weeks prior to study entry;&#xD;
&#xD;
          5. Patients with no measurable lesion (except simple bone metastasis), such as pleural or&#xD;
             pericardial effusion, ascites, et al;&#xD;
&#xD;
          6. Patients have uncontrolled or significant cardiovascular disease, including:&#xD;
&#xD;
               1. Myocardial infarction (&lt; the last 12 months)&#xD;
&#xD;
               2. Uncontrolled angina (&lt; the last 6 months)&#xD;
&#xD;
               3. Congestive heart failure (&lt; the last 6 months), or Left Ventricular Ejection&#xD;
                  Fraction (LVEF) &lt; 50% prior to study entry&#xD;
&#xD;
               4. History of any significant ventricular arrhythmias (e.g., ventricular&#xD;
                  tachycardia, ventricular fibrillation, or TdP)&#xD;
&#xD;
               5. History of significant QT interval prolongation, or Corrected QT Interval (QTc) &gt;&#xD;
                  450 ms prior to study entry&#xD;
&#xD;
               6. History of cerebrovascular accident&#xD;
&#xD;
               7. Symptomatic coronary heart disease requiring treatment with agents&#xD;
&#xD;
          7. The size of fluid area detected by cardiac ultrasonography in cavum pericardium is&#xD;
             ≥10mm during diastolic period;&#xD;
&#xD;
          8. History of organ transplantation;&#xD;
&#xD;
          9. Patients have not recovered from all clinically relevant toxicities to grade 1 due to&#xD;
             prior therapies;&#xD;
&#xD;
         10. Patients have clinical significant gastrointestinal abnormality, e.g., unable to&#xD;
             swallow, chronic diarrhea, ileus, that would interfere the ingestion,transportation or&#xD;
             absorption of oral agents;&#xD;
&#xD;
         11. Active infection [Suffered from active infection of bacteria, virus, fungi,&#xD;
             mycobacteria, parasites, or other infections (excluding nail bed fungal infections),&#xD;
             or require intravenous antibiotic therapy, or antiviral therapy, or hospitalization&#xD;
             due to any significant infection events], or persistent fever within 14 days prior to&#xD;
             study entry;&#xD;
&#xD;
         12. Patients had organ surgery &lt; 6 weeks prior to study entry;&#xD;
&#xD;
         13. Abnormal liver function [total bilirubin &gt; 1.5×upper limit of normal (&gt; 3×upper limit&#xD;
             of normal in case of Gilbert syndrome); Transaminases (ALT, AST) &gt;2.5×upper limit of&#xD;
             normal (&gt;5x upper limit of normal patients with liver metastases), abnormal renal&#xD;
             function (serum creatinine &gt; 1.5×upper limit of normal);&#xD;
&#xD;
         14. Patients with prior invasive malignancies with the exception of curatively-treated&#xD;
             basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ,&#xD;
             unless received curative treatment and with documented evidence of no recurrence in&#xD;
             the past five years;&#xD;
&#xD;
         15. Any mental or cognitive disorder, that would interfere the ability to understand the&#xD;
             informed consent document or the operation and compliance of study;&#xD;
&#xD;
         16. Patients are currently enrolled in another investigational drug study, or completed&#xD;
             within 4 weeks prior to study entry, with the exception of patients only in overall&#xD;
             survival follow-up;&#xD;
&#xD;
         17. Any other condition which is inappropriate for the study in the opinion of the&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zefei Jiang</last_name>
    <role>Principal Investigator</role>
    <affiliation>307 Hospital of PLA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 307th Hospital of Chinese people's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cangzhou Central Hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <zip>061001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tumor Hospital of Hebei Province</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050019</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Ha'erbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Jiangsu</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Nanchang</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University ZhongShan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chidamide</keyword>
  <keyword>breast cancer</keyword>
  <keyword>exemestane</keyword>
  <keyword>Estrogen Receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

